---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-006866"
form_type: "8-K"
ticker: "DYN"
cik: "0001818794"
company_name: "Dyne Therapeutics, Inc."
filed_at: "2022-05-02T23:59:59+00:00"
generated_at: "2026-06-26T02:11:06.757705+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Dyne Therapeutics Reports Q1 2022 Net Loss of $35.6M and Provides Clinical Milestones

## Summary
- Net loss for Q1 2022 was $35.6 million ($0.69 per share) vs. $25.0 million in Q1 2021.
- Cash, cash equivalents and marketable securities totaled $323.2 million as of March 31, 2022.
- R&D expenses were $28.2 million in Q1 2022, up from $18.6 million in Q1 2021.
- Company plans to submit IND response for DYNE-251 in DMD and regulatory filings for DYNE-101 in DM1 in Q2 2022.
- Initiation of multiple ascending dose clinical trials for DYNE-251 and DYNE-101 anticipated in mid-2022.

## SEC filing metadata
- accession: 0000950170-22-006866
- form_type: 8-K
- ticker: DYN
- cik: 0001818794
- company_name: Dyne Therapeutics, Inc.
- filed_at: 2022-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/0000950170-22-006866-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818794/000095017022006866/dyn-20220502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-006866
- JSON: https://secwatch.observer/filing/0000950170-22-006866.json
- Plain text: https://secwatch.observer/filing/0000950170-22-006866.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.